semaglutide cardiovascular trial news The Big of a GLP-1 drug (Wegovy) to Reduce Major Events Semaglutide and Cardiovascular Outcomes in

ClinicalTrials.gov: NCT05929066 (TRIUMPH-1), NCT05929079 (TRIUMPH-2), NCT05882045 (TRIUMPH-3), NCT05931367 (TRIUMPH-4), NCT06383390 (TRIUMPH-Outcomes), NCT06354660 (TRANSCEND-T2D-1)

Meal-induced increments in GFR could serve to enhance the elimination of nitrogen waste products as well as electrolytes such sodium and potassium

We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished

The success stories, like oral semaglutide (Rybelsus), required: Specialized absorption enhancers (SNAC technology)

Semaglutide affects the hypothalamus, a region of the brain responsible for appetite and food intake